Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
Animals
Cytochrome P-450 Enzyme Inhibitors
/ chemistry
Cytochrome P450 Family 4
/ antagonists & inhibitors
Drug Discovery
Humans
Imidazoles
/ chemistry
MCF-7 Cells
Methacrylates
/ pharmacology
Molecular Docking Simulation
Molecular Dynamics Simulation
Molecular Structure
Protein Binding
Rabbits
Structure-Activity Relationship
3D pharmacophores
Breast cancer
CYP4Z1
Enzyme inhibition
Molecular modeling
Virtual screening
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Apr 2021
05 Apr 2021
Historique:
received:
28
09
2020
revised:
27
01
2021
accepted:
29
01
2021
pubmed:
22
2
2021
medline:
27
5
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
Human cytochrome P450 enzyme CYP4Z1 represents a promising target for the treatment of a multitude of malignancies including breast cancer. The most active known non-covalent inhibitor (1-benzylimidazole) only shows low micromolar affinity to CYP4Z1. We report a new, highly active inhibitor for CYP4Z1 showing confirmed binding in an enzymatic assay and an IC
Identifiants
pubmed: 33611185
pii: S0223-5234(21)00104-5
doi: 10.1016/j.ejmech.2021.113255
pii:
doi:
Substances chimiques
Cytochrome P-450 Enzyme Inhibitors
0
Imidazoles
0
Methacrylates
0
CYP4Z1 protein, human
EC 1.14.14.1
Cytochrome P450 Family 4
EC 1.14.14.1
ozagrel
L256JB984D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113255Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.